Fifty 410 vs Remedy Meds: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, month to month and all-in, Fifty 410 charges $199 per 28-day cycle and Remedy Meds $399 per 28-day cycle: $2,587 against $5,187 for a year, so Fifty 410 costs $2,600 less over a year.
Released · Last reviewed · how we verify
On compounded semaglutide, month to month and all-in, Fifty 410 charges $199 per 28-day cycle and Remedy Meds $299 per 28-day cycle: $2,587 against $3,887 for a year, so Fifty 410 costs $1,300 less over a year.
Fifty 410 and Remedy Meds, measure by measure
| Measure | Fifty 410 | Remedy Meds |
|---|---|---|
| Tirzepatide, month to month | $199 (per 28-day cycle) | $399 (per 28-day cycle) |
| Tirzepatide, lowest printed | $149.50 (8-week program at $299, not in all states) | $399 (4-week supply; $279 first month only) |
| Semaglutide, month to month | $199 (per 28-day cycle) | $299 (per 28-day cycle) |
| Semaglutide, lowest printed | $199 (4-week program) | $299 (4-week supply; $179 first month only) |
| Dose pricing | priced by dose or not stated | same price at every dose |
| Membership or program fee | none | none |
| Computed score | 23.5 of 40 (position 8 of 27) | 24.3 of 40 (position 7 of 27) |
| FDA warning letters | 721481 (2026-02-20) | 716830 (2025-09-09) |
| November 20 read | first-party read, changed | first-party read |
Strengths and limitations: which fits whom
Fifty 410 bills every 28 days, which adds a 13th charge to the year. Remedy Meds prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Fifty 410 | tirzepatide | — | $199 |
| Fifty 410 | semaglutide | — | $199 |
| Remedy Meds | tirzepatide | — | $399 |
| Remedy Meds | semaglutide | — | $299 |
Regulatory record
FDA’s warning-letter index lists warning letter 721481 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Fifty 410; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 716830 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Remedy Meds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Fifty 410 or Remedy Meds?
On compounded tirzepatide, month to month and all-in, Fifty 410 charges $199 per 28-day cycle and Remedy Meds $399 per 28-day cycle: $2,587 against $5,187 for a year, so Fifty 410 costs $2,600 less over a year. On compounded semaglutide, month to month and all-in, Fifty 410 charges $199 per 28-day cycle and Remedy Meds $299 per 28-day cycle: $2,587 against $3,887 for a year, so Fifty 410 costs $1,300 less over a year.
Do Fifty 410 and Remedy Meds charge a membership fee?
Fifty 410: no membership fee; Remedy Meds: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Fifty 410 and Remedy Meds medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Fifty 410 pricing page (read November 20, 2026)
- Remedy Meds pricing page (read November 20, 2026)
- FDA warning letter 721481 to Fifty 410 (dated 2026-02-20, posted 2026-03-03)
- FDA warning letter 716830 to Remedy Meds (dated 2025-09-09, posted 2025-09-16)